{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,9,23]],"date-time":"2025-09-23T14:18:04Z","timestamp":1758637084323},"reference-count":56,"publisher":"Springer Science and Business Media LLC","issue":"9","license":[{"start":{"date-parts":[[2020,8,12]],"date-time":"2020-08-12T00:00:00Z","timestamp":1597190400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2020,8,12]],"date-time":"2020-08-12T00:00:00Z","timestamp":1597190400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Internist"],"published-print":{"date-parts":[[2020,9]]},"DOI":"10.1007\/s00108-020-00849-2","type":"journal-article","created":{"date-parts":[[2020,8,12]],"date-time":"2020-08-12T10:04:03Z","timestamp":1597226643000},"page":"969-979","update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Erdheim-Chester-Erkrankung \u2013 eine histiozyt\u00e4re Multisystemerkrankung mit ungew\u00f6hnlicher Nierenbeteiligung"],"prefix":"10.1007","volume":"61","author":[{"given":"S.","family":"Dasdelen","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"F.","family":"B\u00fcschek","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2020,8,12]]},"reference":[{"issue":"10","key":"849_CR1","doi-asserted-by":"publisher","first-page":"2054","DOI":"10.1016\/j.mayocp.2019.02.023","volume":"94","author":"G Goyal","year":"2019","unstructured":"Goyal\u00a0G, Young\u00a0JR, Koster\u00a0MJ et al (2019) The mayo clinic histiocytosis working group consensus statement for the diagnosis and evaluation of adult patients with Histiocytic neoplasms: Erdheim-Chester disease, Langerhans cell histiocytosis, and Rosai-Dorfman disease. Mayo Clin Proc 94(10):2054\u20132071. https:\/\/doi.org\/10.1016\/j.mayocp.2019.02.023","journal-title":"Mayo Clin Proc"},{"issue":"5","key":"849_CR2","doi-asserted-by":"publisher","first-page":"924","DOI":"10.1016\/j.mayocp.2019.01.026","volume":"94","author":"A Poellinger","year":"2019","unstructured":"Poellinger\u00a0A, Hrycyk\u00a0J (2019) Erdheim-Chester disease. Mayo Clin Proc 94(5):924\u2013925. https:\/\/doi.org\/10.1016\/j.mayocp.2019.01.026","journal-title":"Mayo Clin Proc"},{"issue":"1","key":"849_CR3","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1111\/bjd.15860","volume":"178","author":"F Chasset","year":"2018","unstructured":"Chasset\u00a0F, Haroche\u00a0J (2018) Cutaneous manifestations of paediatric Erdheim-Chester disease, a\u00a0histiocytosis of the \u201cL\u201d group. Br J Dermatol 178(1):31\u201332. https:\/\/doi.org\/10.1111\/bjd.15860","journal-title":"Br J Dermatol"},{"issue":"4","key":"849_CR4","doi-asserted-by":"publisher","first-page":"483","DOI":"10.1182\/blood-2014-03-561381","volume":"124","author":"EL Diamond","year":"2014","unstructured":"Diamond\u00a0EL, Dagna\u00a0L, Hyman\u00a0DM et al (2014) Consensus guidelines for the diagnosis and clinical management of Erdheim-Chester disease. Blood 124(4):483\u2013492. https:\/\/doi.org\/10.1182\/blood-2014-03-561381","journal-title":"Blood"},{"key":"849_CR5","doi-asserted-by":"publisher","first-page":"E114","DOI":"10.1002\/ajh.25055","volume":"93","author":"F Cohen-Aubart","year":"2018","unstructured":"Cohen-Aubart\u00a0F, Emile\u00a0J\u2011F, Carrat\u00a0F et al (2018) Phenotypes and survival in Erdheim-Chester disease: results from a\u00a0165-patient cohort. Am J Hematol 93:E114\u2013E117. https:\/\/doi.org\/10.1002\/ajh.25055","journal-title":"Am J Hematol"},{"issue":"2","key":"849_CR6","doi-asserted-by":"publisher","first-page":"561","DOI":"10.1007\/BF01942684","volume":"279","author":"W Chester","year":"1930","unstructured":"Chester\u00a0W (1930) \u00dcber Lipoidgranulomatose. Virchows Arch Pathol Anat Physiol Klin Med 279(2):561\u2013602. https:\/\/doi.org\/10.1007\/BF01942684","journal-title":"Virchows Arch Pathol Anat Physiol Klin Med"},{"key":"849_CR7","unstructured":"Jaffe\u00a0H (1972) Metabolic, degenerative and inflammatory diseases of bone and jones. Lea & Fiebiger, Philadelphia"},{"issue":"12","key":"849_CR8","doi-asserted-by":"publisher","first-page":"4018","DOI":"10.1002\/art.22280","volume":"54","author":"A Stoppacciaro","year":"2006","unstructured":"Stoppacciaro\u00a0A, Ferrarini\u00a0M, Salmaggi\u00a0C et al (2006) Immunohistochemical evidence of a\u00a0cytokine and chemokine network in three patients with Erdheim-Chester disease: implications for pathogenesis. Arthritis Rheum 54(12):4018\u20134022. https:\/\/doi.org\/10.1002\/art.22280","journal-title":"Arthritis Rheum"},{"issue":"11","key":"849_CR9","doi-asserted-by":"publisher","first-page":"1919","DOI":"10.1182\/blood-2010-04-279083","volume":"116","author":"G Badalian-Very","year":"2010","unstructured":"Badalian-Very\u00a0G, Vergilio\u00a0J\u2011A, Degar\u00a0BA et al (2010) Recurrent BRAF mutations in Langerhans cell histiocytosis. Blood 116(11):1919\u20131923. https:\/\/doi.org\/10.1182\/blood-2010-04-279083","journal-title":"Blood"},{"issue":"2","key":"849_CR10","doi-asserted-by":"publisher","first-page":"154","DOI":"10.1158\/2159-8290.CD-15-0913","volume":"6","author":"EL Diamond","year":"2016","unstructured":"Diamond\u00a0EL, Durham\u00a0BH, Haroche\u00a0J et\u00a0al (2016) Diverse and targetable kinase alterations drive histiocytic neoplasms. Cancer Discov 6(2):154\u2013165. https:\/\/doi.org\/10.1158\/2159-8290.CD-15-0913","journal-title":"Cancer Discov"},{"issue":"9","key":"849_CR11","doi-asserted-by":"publisher","first-page":"1495","DOI":"10.1182\/blood-2012-07-446286","volume":"121","author":"J Haroche","year":"2013","unstructured":"Haroche\u00a0J, Cohen-Aubart\u00a0F, Emile\u00a0J\u2011F et al (2013) Dramatic efficacy of vemurafenib in both multisystemic and refractory Erdheim-Chester disease and Langerhans cell histiocytosis harboring the BRAF V600E mutation. Blood 121(9):1495\u20131500. https:\/\/doi.org\/10.1182\/blood-2012-07-446286","journal-title":"Blood"},{"issue":"22","key":"849_CR12","doi-asserted-by":"publisher","first-page":"2672","DOI":"10.1182\/blood-2016-01-690636","volume":"127","author":"J-F Emile","year":"2016","unstructured":"Emile\u00a0J\u2011F, Abla\u00a0O, Fraitag\u00a0S et al (2016) Revised classification of histiocytoses and neoplasms of the macrophage-dendritic cell lineages. Blood 127(22):2672\u20132681. https:\/\/doi.org\/10.1182\/blood-2016-01-690636","journal-title":"Blood"},{"issue":"1","key":"849_CR13","doi-asserted-by":"publisher","first-page":"305","DOI":"10.1210\/jc.2015-3357","volume":"101","author":"C Courtillot","year":"2016","unstructured":"Courtillot\u00a0C, Laugier Robiolle\u00a0S, Cohen Aubart\u00a0F et al (2016) Endocrine manifestations in a\u00a0monocentric cohort of 64 patients with Erdheim-Chester disease. J\u00a0Clin Endocrinol Metab 101(1):305\u2013313. https:\/\/doi.org\/10.1210\/jc.2015-3357","journal-title":"J Clin Endocrinol Metab"},{"key":"849_CR14","doi-asserted-by":"publisher","first-page":"2783","DOI":"10.1182\/blood-2010-10-313510","volume":"117","author":"L Arnaud","year":"2011","unstructured":"Arnaud\u00a0L, Gorochov\u00a0G, Charlotte\u00a0F et al (2011) Systemic perturbation of cytokine and chemokine networks in Erdheim-Chester disease: a\u00a0single-center series of 37 patients. Blood 117:2783\u20132790. https:\/\/doi.org\/10.1182\/blood-2010-10-313510","journal-title":"Blood"},{"key":"849_CR15","doi-asserted-by":"publisher","first-page":"1655","DOI":"10.1182\/blood-2014-05-577361","volume":"124","author":"NA Brown","year":"2014","unstructured":"Brown\u00a0NA, Furtado\u00a0LV, Betz\u00a0BL et\u00a0al (2014) High prevalence of somatic MAP2K1 mutations in BRAF V600E\u2013negative Langerhans cell histiocytosis. Blood 124:1655\u20131658. https:\/\/doi.org\/10.1182\/blood-2014-05-577361","journal-title":"Blood"},{"key":"849_CR16","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1007\/s00393-018-0566-7","volume":"78","author":"J Knitza","year":"2019","unstructured":"Knitza\u00a0J, Kampylafka\u00a0E, Wacker\u00a0J et al (2019) Morbus Erdheim-Chester: Eine wichtige Differenzialdiagnose und ihre Leitsymptome. Z\u00a0Rheumatol 78:66\u201371. https:\/\/doi.org\/10.1007\/s00393-018-0566-7","journal-title":"Z Rheumatol"},{"issue":"2","key":"849_CR17","doi-asserted-by":"publisher","first-page":"632","DOI":"10.1148\/radiol.2382041525","volume":"238","author":"E Dion","year":"2006","unstructured":"Dion\u00a0E, Graef\u00a0C, Miquel\u00a0A et al (2006) Bone involvement in Erdheim-Chester disease: imaging findings including periostitis and partial epiphyseal involvement. Radiology 238(2):632\u2013639. https:\/\/doi.org\/10.1148\/radiol.2382041525","journal-title":"Radiology"},{"key":"849_CR18","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1016\/S0889-857X(21)01069-3","volume":"16","author":"CJ Michet","year":"1990","unstructured":"Michet\u00a0CJ (1990) Vasculitis and relapsing polychondritis. Rheum Dis Clin North Am 16:441\u2013444","journal-title":"Rheum Dis Clin North Am"},{"issue":"8","key":"849_CR19","doi-asserted-by":"publisher","first-page":"604","DOI":"10.3760\/cma.j.issn.1001-0939.2017.08.012","volume":"40","author":"T Lu","year":"2017","unstructured":"Lu\u00a0T, Wang\u00a0S, Huang\u00a0H et al (2017) Clinical and pathological characteristics of Erdheim-Chester disease involving the lungs. Zhonghua Jie He He Hu Xi Za Zhi 40(8):604\u2013610. https:\/\/doi.org\/10.3760\/cma.j.issn.1001-0939.2017.08.012","journal-title":"Zhonghua Jie He He Hu Xi Za Zhi"},{"issue":"2","key":"849_CR20","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1111\/echo.14231","volume":"36","author":"AS Ghotra","year":"2019","unstructured":"Ghotra\u00a0AS, Thompson\u00a0K, Lopez-Mattei\u00a0J et al (2019) Cardiovascular manifestations of Erdheim-Chester disease. Echocardiography 36(2):229\u2013236. https:\/\/doi.org\/10.1111\/echo.14231","journal-title":"Echocardiography"},{"issue":"12","key":"849_CR21","doi-asserted-by":"publisher","first-page":"2118","DOI":"10.1093\/rheumatology\/kew331","volume":"55","author":"P Kraniotis","year":"2016","unstructured":"Kraniotis\u00a0P, Daoussis\u00a0D (2016) Periaortitis, hairy kidneys and bone lesions. Rheumatology (Oxford) 55(12):2118. https:\/\/doi.org\/10.1093\/rheumatology\/kew331","journal-title":"Rheumatology (Oxford)"},{"issue":"11","key":"849_CR22","doi-asserted-by":"publisher","first-page":"1066","DOI":"10.1016\/j.lpm.2016.07.010","volume":"45","author":"V Jean-Michel","year":"2016","unstructured":"Jean-Michel\u00a0V, Coustans\u00a0M, Wehbe\u00a0B, Metes\u00a0I, Siohan\u00a0P (2016) Erdheim Chester disease: a rare obstructive case of acute renal failure. Presse Med 45(11):1066\u20131069. https:\/\/doi.org\/10.1016\/j.lpm.2016.07.010","journal-title":"Presse Med"},{"issue":"3","key":"849_CR23","doi-asserted-by":"publisher","first-page":"979","DOI":"10.1007\/s00261-016-0937-y","volume":"42","author":"WJ Triffo","year":"2017","unstructured":"Triffo\u00a0WJ, Dyer\u00a0RB (2017) The \u201chairy kidney\u201d sign. Abdom Radiol (NY) 42(3):979\u2013980. https:\/\/doi.org\/10.1007\/s00261-016-0937-y","journal-title":"Abdom Radiol (NY)"},{"issue":"4","key":"849_CR24","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1080\/01676830.2016.1176211","volume":"35","author":"H Merritt","year":"2016","unstructured":"Merritt\u00a0H, Pfeiffer\u00a0ML, Richani\u00a0K, Phillips\u00a0ME (2016) Erdheim-Chester disease with orbital involvement: case report and ophthalmic literature review. Orbit 35(4):221\u2013226. https:\/\/doi.org\/10.1080\/01676830.2016.1176211","journal-title":"Orbit"},{"issue":"12","key":"849_CR25","doi-asserted-by":"publisher","first-page":"986","DOI":"10.1093\/jnen\/nlx095","volume":"76","author":"Z Pan","year":"2017","unstructured":"Pan\u00a0Z, Kleinschmidt-DeMasters\u00a0BK (2017) CNS Erdheim-Chester disease: a challenge to diagnose. J\u00a0Neuropathol Exp Neurol 76(12):986\u2013996. https:\/\/doi.org\/10.1093\/jnen\/nlx095","journal-title":"J Neuropathol Exp Neurol"},{"issue":"6","key":"849_CR26","doi-asserted-by":"publisher","first-page":"510","DOI":"10.1007\/s001050000080","volume":"52","author":"DF Watermann","year":"2001","unstructured":"Watermann\u00a0DF, Kiesewetter\u00a0F, Frosch\u00a0PJ (2001) Hautmanifestationen der Erdheim-Chester-Krankheit Fallbericht und Literatur\u00fcbersicht. Hautarzt 52(6):510\u2013517. https:\/\/doi.org\/10.1007\/s001050000080","journal-title":"Hautarzt"},{"issue":"10","key":"849_CR27","doi-asserted-by":"publisher","first-page":"3330","DOI":"10.1002\/art.22165","volume":"54","author":"J Haroche","year":"2006","unstructured":"Haroche\u00a0J, Amoura\u00a0Z, Trad\u00a0SG et al (2006) Variability in the efficacy of interferon-alpha in Erdheim-Chester disease by patient and site of involvement: results in eight patients. Arthritis Rheum 54(10):3330\u20133336. https:\/\/doi.org\/10.1002\/art.22165","journal-title":"Arthritis Rheum"},{"key":"849_CR28","doi-asserted-by":"publisher","first-page":"581","DOI":"10.1038\/modpathol.2017.160","volume":"31","author":"N Ozkaya","year":"2018","unstructured":"Ozkaya\u00a0N, Rosenblum\u00a0MK, Durham\u00a0BH et\u00a0al (2018) The histopathology of Erdheim\u2013Chester disease: a\u00a0comprehensive review of a\u00a0molecularly characterized cohort. Mod Pathol 31:581\u2013597. https:\/\/doi.org\/10.1038\/modpathol.2017.160","journal-title":"Mod Pathol"},{"key":"849_CR29","doi-asserted-by":"publisher","first-page":"423","DOI":"10.1016\/S0212-6982(05)74190-2","volume":"24","author":"C Ramos-Font","year":"2005","unstructured":"Ramos-Font\u00a0C, Rebollo Aguirre\u00a0AC, Moral Ruiz\u00a0A et al (2005) Occult femoral neck fracture in a\u00a0patient with Erdheim-Chester disease. Rev Esp Med Nucl 24:423","journal-title":"Rev Esp Med Nucl"},{"key":"849_CR30","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1007\/s11102-006-6598-z","volume":"9","author":"J-A Rivera","year":"2006","unstructured":"Rivera\u00a0J\u2011A (2006) Lymphocytic hypophysitis: disease spectrum and approach to diagnosis and therapy. Pituitary 9:35\u201345. https:\/\/doi.org\/10.1007\/s11102-006-6598-z","journal-title":"Pituitary"},{"key":"849_CR31","doi-asserted-by":"publisher","first-page":"32","DOI":"10.5693\/djo.02.2015.09.002","volume":"22","author":"DD Sevgi","year":"2015","unstructured":"Sevgi\u00a0DD, Sobrin\u00a0L, Papaliodis\u00a0GN (2015) Cogan syndrome with severe medium and large vessel vasculitis. Digit J Ophthalmol 22:32\u201334. https:\/\/doi.org\/10.5693\/djo.02.2015.09.002","journal-title":"Digit J Ophthalmol"},{"key":"849_CR32","doi-asserted-by":"publisher","first-page":"1059","DOI":"10.1007\/s00108-019-00666-2","volume":"60","author":"PM Villiger","year":"2019","unstructured":"Villiger\u00a0PM (2019) Gro\u00dfgef\u00e4\u00dfvaskulitiden \u2013 Riesenzellarteriitis und Takayasu-Arteriitis. Internist 60:1059\u20131073. https:\/\/doi.org\/10.1007\/s00108-019-00666-2","journal-title":"Internist"},{"key":"849_CR33","doi-asserted-by":"publisher","first-page":"191","DOI":"10.36141\/svdld.v34i2.5439","volume":"34","author":"WIQ de Waard","year":"2017","unstructured":"de Waard\u00a0WIQ, van Battum\u00a0PLH, Mostard\u00a0RLM (2017) Central diabetes insipidus due to sarcoidosis. Sarcoidosis Vasc Diffuse Lung Dis 34:191\u2013193. https:\/\/doi.org\/10.36141\/svdld.v34i2.5439","journal-title":"Sarcoidosis Vasc Diffuse Lung Dis"},{"key":"849_CR34","doi-asserted-by":"publisher","first-page":"1929","DOI":"10.1182\/blood.2019003507","volume":"135","author":"G Goyal","year":"2020","unstructured":"Goyal\u00a0G, Heaney\u00a0ML, Collin\u00a0M et al (2020) Erdheim-Chester disease: consensus recommendations for evaluation, diagnosis, and treatment in the molecular era. Blood 135:1929\u20131945. https:\/\/doi.org\/10.1182\/blood.2019003507","journal-title":"Blood"},{"issue":"6","key":"849_CR35","doi-asserted-by":"publisher","first-page":"945","DOI":"10.1016\/s0002-9394(01)01141-2","volume":"132","author":"B Esmaeli","year":"2001","unstructured":"Esmaeli\u00a0B, Ahmadi\u00a0A, Tang\u00a0R, Schiffman\u00a0J, Kurzrock\u00a0R (2001) Interferon therapy for orbital infiltration secondary to Erdheim-Chester disease. Am J Ophthalmol 132(6):945\u2013947. https:\/\/doi.org\/10.1016\/s0002-9394(01)01141-2","journal-title":"Am J Ophthalmol"},{"issue":"2","key":"849_CR36","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1016\/j.rdc.2013.02.011","volume":"39","author":"J Haroche","year":"2013","unstructured":"Haroche\u00a0J, Arnaud\u00a0L, Cohen-Aubart\u00a0F et al (2013) Erdheim-Chester disease. Rheum Dis Clin North Am 39(2):299\u2013311. https:\/\/doi.org\/10.1016\/j.rdc.2013.02.011","journal-title":"Rheum Dis Clin North Am"},{"issue":"6","key":"849_CR37","doi-asserted-by":"publisher","first-page":"907","DOI":"10.1016\/j.semarthrit.2011.11.004","volume":"41","author":"B Hervier","year":"2012","unstructured":"Hervier\u00a0B, Arnaud\u00a0L, Charlotte\u00a0F et al (2012) Treatment of Erdheim-Chester disease with long-term high-dose interferon\u2011\u03b1. Semin Arthritis Rheum 41(6):907\u2013913. https:\/\/doi.org\/10.1016\/j.semarthrit.2011.11.004","journal-title":"Semin Arthritis Rheum"},{"issue":"1","key":"849_CR38","doi-asserted-by":"publisher","first-page":"e21","DOI":"10.1016\/j.leukres.2009.07.026","volume":"34","author":"HI Suzuki","year":"2010","unstructured":"Suzuki\u00a0HI, Hosoya\u00a0N, Miyagawa\u00a0K et al (2010) Erdheim-Chester disease: multisystem involvement and management with interferon-alpha. Leuk Res 34(1):e21\u2013e24. https:\/\/doi.org\/10.1016\/j.leukres.2009.07.026","journal-title":"Leuk Res"},{"issue":"10","key":"849_CR39","doi-asserted-by":"publisher","first-page":"1034","DOI":"10.1056\/NEJM200409023511022","volume":"351","author":"L Montella","year":"2004","unstructured":"Montella\u00a0L, Insabato\u00a0L, Palmieri\u00a0G (2004) Imatinib mesylate for cerebral Langerhans\u2019-cell histiocytosis. N\u00a0Engl J Med 351(10):1034\u20131035. https:\/\/doi.org\/10.1056\/NEJM200409023511022","journal-title":"N Engl J Med"},{"key":"849_CR40","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1186\/1750-1172-8-72","volume":"8","author":"M Girschikofsky","year":"2013","unstructured":"Girschikofsky\u00a0M, Arico\u00a0M, Castillo\u00a0D et al (2013) Management of adult patients with Langerhans cell histiocytosis: recommendations from an expert panel on behalf of Euro-Histio-Net. Orphanet J Rare Dis 8:72. https:\/\/doi.org\/10.1186\/1750-1172-8-72","journal-title":"Orphanet J Rare Dis"},{"issue":"11","key":"849_CR41","doi-asserted-by":"publisher","first-page":"5413","DOI":"10.1182\/blood-2008-03-148304","volume":"111","author":"J Haroche","year":"2008","unstructured":"Haroche\u00a0J, Amoura\u00a0Z, Charlotte\u00a0F et al (2008) Imatinib mesylate for platelet-derived growth factor receptor-beta-positive Erdheim-Chester histiocytosis. Blood 111(11):5413\u20135415. https:\/\/doi.org\/10.1182\/blood-2008-03-148304","journal-title":"Blood"},{"issue":"6","key":"849_CR42","doi-asserted-by":"publisher","first-page":"844","DOI":"10.1136\/bjo.2003.035584","volume":"88","author":"C Myra","year":"2004","unstructured":"Myra\u00a0C, Sloper\u00a0L, Tighe\u00a0PJ et al (2004) Treatment of Erdheim-Chester disease with cladribine: a\u00a0rational approach. Br J Ophthalmol 88(6):844\u2013847. https:\/\/doi.org\/10.1136\/bjo.2003.035584","journal-title":"Br J Ophthalmol"},{"issue":"10","key":"849_CR43","doi-asserted-by":"publisher","first-page":"1163","DOI":"10.1182\/blood-2015-01-620377","volume":"126","author":"D Gianfreda","year":"2015","unstructured":"Gianfreda\u00a0D, Nicastro\u00a0M, Galetti\u00a0M et al (2015) Sirolimus plus prednisone for Erdheim-Chester disease: an open-label trial. Blood 126(10):1163. https:\/\/doi.org\/10.1182\/blood-2015-01-620377","journal-title":"Blood"},{"issue":"2","key":"849_CR44","first-page":"232","volume":"21","author":"G Mossetti","year":"2003","unstructured":"Mossetti\u00a0G, Rendina\u00a0D, Numis\u00a0FG, Somma\u00a0P, Postiglione\u00a0L, Nunziata\u00a0V (2003) Biochemical markers of bone turnover, serum levels of interleukin-6\/interleukin\u20116 soluble receptor and bisphosphonate treatment in Erdheim-Chester disease. Clin Exp Rheumatol 21(2):232\u2013236","journal-title":"Clin Exp Rheumatol"},{"issue":"5","key":"849_CR45","doi-asserted-by":"publisher","first-page":"598","DOI":"10.1038\/s41379-018-0168-6","volume":"32","author":"KTE Chang","year":"2019","unstructured":"Chang\u00a0KTE, Tay\u00a0AZE, Kuick\u00a0CH et al (2019) ALK-positive histiocytosis: an expanded clinicopathologic spectrum and frequent presence of KIF5B-ALK fusion. Mod Pathol 32(5):598\u2013608. https:\/\/doi.org\/10.1038\/s41379-018-0168-6","journal-title":"Mod Pathol"},{"issue":"11","key":"849_CR46","doi-asserted-by":"publisher","first-page":"1377","DOI":"10.1182\/blood-2017-03-771873","volume":"130","author":"F Cohen Aubart","year":"2017","unstructured":"Cohen Aubart\u00a0F, Emile\u00a0J\u2011F, Carrat\u00a0F et al (2017) Targeted therapies in 54 patients with Erdheim-Chester disease, including follow-up after interruption (the LOVE study). Blood 130(11):1377\u20131380. https:\/\/doi.org\/10.1182\/blood-2017-03-771873","journal-title":"Blood"},{"issue":"1","key":"849_CR47","doi-asserted-by":"publisher","first-page":"150","DOI":"10.1111\/bjh.14284","volume":"180","author":"F Cohen Aubart","year":"2018","unstructured":"Cohen Aubart\u00a0F, Emile\u00a0J\u2011F, Maksud\u00a0P et al (2018) Efficacy of the MEK inhibitor cobimetinib for wild-type BRAF Erdheim-Chester disease. Br J Haematol 180(1):150\u2013153. https:\/\/doi.org\/10.1111\/bjh.14284","journal-title":"Br J Haematol"},{"issue":"10","key":"849_CR48","doi-asserted-by":"publisher","first-page":"1989","DOI":"10.1002\/ccr3.2297","volume":"7","author":"AC King","year":"2019","unstructured":"King\u00a0AC, Diamond\u00a0EL, Orozco\u00a0JS et al (2019) Cobimetinib-induced \u201cdropped head syndrome\u201d and subsequent disease management in an Erdheim-Chester patient. Clin Case Rep 7(10):1989\u20131993. https:\/\/doi.org\/10.1002\/ccr3.2297","journal-title":"Clin Case Rep"},{"issue":"7","key":"849_CR49","doi-asserted-by":"publisher","first-page":"879","DOI":"10.1182\/blood-2016-09-740217","volume":"129","author":"TM Nordmann","year":"2017","unstructured":"Nordmann\u00a0TM, Juengling\u00a0FD, Recher\u00a0M et al (2017) Trametinib after disease reactivation under dabrafenib in Erdheim-Chester disease with both BRAF and KRAS mutations. Blood 129(7):879\u2013882. https:\/\/doi.org\/10.1182\/blood-2016-09-740217","journal-title":"Blood"},{"issue":"3","key":"849_CR50","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1097\/00005792-199605000-00005","volume":"75","author":"C Veyssier-Belot","year":"1996","unstructured":"Veyssier-Belot\u00a0C, Cacoub\u00a0P, Caparros-Lefebvre\u00a0D et al (1996) Erdheim-Chester disease clinical and radiologic characteristics of 59 cases. Medicine 75(3):157\u2013169","journal-title":"Medicine"},{"issue":"10","key":"849_CR51","doi-asserted-by":"publisher","first-page":"2778","DOI":"10.1182\/blood-2010-06-294108","volume":"117","author":"L Arnaud","year":"2011","unstructured":"Arnaud\u00a0L, Hervier\u00a0B, N\u00e9el\u00a0A et al (2011) CNS involvement and treatment with interferon\u2011\u03b1 are independent prognostic factors in Erdheim-Chester disease: a\u00a0multicenter survival analysis of 53 patients. Blood 117(10):2778\u20132782. https:\/\/doi.org\/10.1182\/blood-2010-06-294108","journal-title":"Blood"},{"issue":"557","key":"849_CR52","first-page":"743","volume":"13","author":"R Andr\u00e9","year":"2017","unstructured":"Andr\u00e9\u00a0R, Seebach\u00a0JD (2017) Erdheim-Chester disease: a\u00a0differential diagnosis of retroperitoneal fibrosis. Rev Med Suisse 13(557):743\u2013747","journal-title":"Rev Med Suisse"},{"issue":"20","key":"849_CR53","doi-asserted-by":"publisher","first-page":"4070","DOI":"10.1182\/blood-2010-04-279240","volume":"116","author":"A Aouba","year":"2010","unstructured":"Aouba\u00a0A, Georgin-Lavialle\u00a0S, Pagnoux\u00a0C et al (2010) Rationale and efficacy of interleukin\u20111 targeting in Erdheim-Chester disease. Blood 116(20):4070\u20134076. https:\/\/doi.org\/10.1182\/blood-2010-04-279240","journal-title":"Blood"},{"issue":"28","key":"849_CR54","doi-asserted-by":"publisher","first-page":"e286","DOI":"10.1200\/JCO.2012.41.9911","volume":"30","author":"L Dagna","year":"2012","unstructured":"Dagna\u00a0L, Corti\u00a0A, Langheim\u00a0S et al (2012) Tumor necrosis factor \u03b1 as a\u00a0master regulator of inflammation in Erdheim-Chester disease: rationale for the treatment of patients with infliximab. J\u00a0Clin Oncol 30(28):e286\u2013290. https:\/\/doi.org\/10.1200\/JCO.2012.41.9911","journal-title":"J Clin Oncol"},{"issue":"9","key":"849_CR55","doi-asserted-by":"publisher","first-page":"e781","DOI":"10.7759\/cureus.781","volume":"8","author":"AA Dave","year":"2016","unstructured":"Dave\u00a0AA, Gutschow\u00a0SE, Walker\u00a0CM (2016) A case of incidentally-diagnosed Erdheim-Chester disease. Cureus 8(9):e781. https:\/\/doi.org\/10.7759\/cureus.781","journal-title":"Cureus"},{"issue":"3","key":"849_CR56","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1002\/(SICI)1096-911X(199709)29:3<157::AID-MPO1>3.0.CO;2-C","volume":"29","author":"BE Favara","year":"1997","unstructured":"Favara\u00a0BE, Feller\u00a0AC, Pauli\u00a0M et al (1997) Contemporary classification of histiocytic disorders. Med Pediatr Oncol 29(3):157\u2013166. https:\/\/doi.org\/10.1002\/(SICI)1096-911X(199709)29:3\u3008157::AID-MPO1\u30093.0.CO;2\u2011C","journal-title":"Med Pediatr Oncol"}],"container-title":["Der Internist"],"original-title":[],"language":"de","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00108-020-00849-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00108-020-00849-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00108-020-00849-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,8,11]],"date-time":"2021-08-11T23:06:52Z","timestamp":1628723212000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00108-020-00849-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,8,12]]},"references-count":56,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2020,9]]}},"alternative-id":["849"],"URL":"https:\/\/doi.org\/10.1007\/s00108-020-00849-2","relation":{},"ISSN":["0020-9554","1432-1289"],"issn-type":[{"value":"0020-9554","type":"print"},{"value":"1432-1289","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,8,12]]},"assertion":[{"value":"12 August 2020","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Einhaltung ethischer Richtlinien"}},{"value":"S.\u00a0Dasdelen und F.\u00a0B\u00fcschek geben an, dass kein Interessenkonflikt besteht.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Interessenkonflikt"}},{"value":"F\u00fcr diesen Beitrag wurden von den Autoren keine Studien an Menschen oder Tieren durchgef\u00fchrt. F\u00fcr die aufgef\u00fchrten Studien gelten die jeweils dort angegebenen ethischen Richtlinien. F\u00fcr Bildmaterial oder anderweitige Angaben innerhalb des Manuskripts, \u00fcber die Patienten zu identifizieren sind, liegt von ihnen und\/oder ihren gesetzlichen Vertretern eine schriftliche Einwilligung vor.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Interessenkonflikt"}}]}}